Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 12;34(7):doaa120.
doi: 10.1093/dote/doaa120.

Treatment with compounded fluticasone suspension improves the clinical, endoscopic, and histologic features of eosinophilic esophagitis

Corey J Ketchem  1 , Craig C Reed  1 , Zoe Stefanadis  2 , Evan S Dellon  1
Affiliations

Treatment with compounded fluticasone suspension improves the clinical, endoscopic, and histologic features of eosinophilic esophagitis

Corey J Ketchem et al. Dis Esophagus. .

Abstract

No approved medication exists for the treatment of eosinophilic esophagitis (EoE) in the United States, which forces patients to utilize off-label drugs and/or create their own formulations. We assessed the efficacy of a standardized compounded fluticasone suspension. To do this, we performed a retrospective cohort study identifying all EoE patients treated with compounded fluticasone. Compounded fluticasone was prescribed during routine clinical care and dispensed by a specialty compounding pharmacy. Clinical data were extracted from medical records. Outcomes (symptomatic, endoscopic, and histologic) were assessed after the initial and last compounded fluticasone treatment in our system. There were 27 included patients (mean age 34.2; 67% male; 96% white) treated for a mean length of 5.4 ± 4.4 months. The majority (89%) previously utilized dietary elimination or topical corticosteroids, and many (75%) had primary non-response or secondary loss of response to these treatments. After starting compounded fluticasone, symptoms and endoscopic findings improved [dysphagia (89 vs. 56%, P = 0.005), food impaction (59 vs. 4%, P = 0.003), heartburn (26 vs. 4%, P = 0.01), chest pain (26 vs. 8%, P = 0.05), white plaques (63 vs. 32%; P = 0.005), furrows (81 vs. 60%; P = 0.06), and edema (15 vs. 4%; P = 0.16)]. The median of the peak eosinophil counts decreased from 52 to 37 eos/hpf (P = 0.10) and 35% of patients achieved <15 eos/hpf. In conclusion, compounded fluticasone provided a significant improvement in symptoms and endoscopic findings, with more than a third achieving histologic response in a treatment refractory EoE population. Compounded fluticasone should be considered as an EoE management option.

Keywords: clinical pharmacy; eosinophilic esophagitis; fluticasone; outcomes research.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Symptom response in subjects with prior non-response, pre-treatment versus post-treatment.
Fig. 2
Fig. 2
Endoscopic response in subjects with prior non-response, pre-treatment versus post-treatment.
See this image and copyright information in PMC

References

    1. Straumann A, Katzka D A. Diagnosis and treatment of eosinophilic esophagitis. Gastroenterology 2018; 154: 346–59. - PubMed
    1. Furuta G T, Liacouras C A, Collins M H et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007; 133: 1342–63. - PubMed
    1. Landres R T, Kuster G G, Strum W B. Eosinophilic esophagitis in a patient with vigorous achalasia. Gastroenterology 1978; 74: 1298–301. - PubMed
    1. Attwood S E, Smyrk T C, Demeester T R, Jones J B. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci 1993; 38: 109–16. - PubMed
    1. Straumann A, Spichtin H P, Bernoulli R, Loosli J, Vögtlin J. Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings. Schweiz Med Wochenschr 1994; 124: 1419–29. - PubMed